The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
about
Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression AnalysisPalliative Care in Older Patients With CancerSocioeconomic Disparities in Mortality Among Women With Incident Breast Cancer Before and After Implementation of Medicare Part DImpact of pharmacy channel on adherence to oral oncolytics.Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.A Systematic Review of Adherence to Oral Antineoplastic TherapiesPsychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast CancerAssociation of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions.Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.The Payer and Patient Cost Burden of Open Breast Conserving Procedures Following Percutaneous Breast Biopsy.Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
P2860
Q26779595-45C361FD-BE46-471C-85AA-09424A09D417Q28085144-220E96D9-6235-4D3B-BC92-021585031D83Q33563718-57125014-0F98-4362-B22C-31C5D00180E4Q33815415-530A63F0-C540-4AE0-8F81-9D2CAAD50A6CQ35060868-1B1F8F95-0B1E-47E2-BF36-CD00ABCAB573Q35168777-D52506E6-B096-4C23-8E43-F849D34F00A7Q36087210-C4C3C89F-5175-41FA-B9F4-67B30E0F7237Q36673490-67CF04D5-175B-4EC5-AB8F-09F153E2035FQ36901989-49C3746C-2D33-474B-8CEC-0C96E3420669Q37065603-49C18A3F-2D15-478D-9CD3-7F0E6913F7CFQ37070101-D5643CE3-5C65-4BB4-B7EA-6C1CF52B03D9Q37669380-01AED627-020B-4C8E-9998-A4C223FAB3FDQ38962407-D77901BA-4C55-4223-BE30-4078F102F09BQ39052545-2C6AA73C-908B-4BC3-A17B-9F5114DC7236Q39315948-0FCC14AB-D9A4-4974-A191-090E7605ACFDQ40454138-5B8F4B96-A6CC-40EF-B7C0-F1CCD2C9F7DCQ42319245-E453DCDF-15D4-477F-A246-A7D2C17DD1DDQ44446068-CA8930B4-617A-43C1-9401-AF3934BC0BC8Q47886197-2B42A21B-9924-4C76-AB5F-A2ECFE628CEBQ55028524-18EFC9C5-BD0A-4750-8D8A-8112222BE81BQ55519528-79D589AF-D57D-466D-840F-17088CCB33F9
P2860
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The change from brand-name to ...... for early-stage breast cancer.
@ast
The change from brand-name to ...... for early-stage breast cancer.
@en
The change from brand-name to ...... for early-stage breast cancer.
@nl
type
label
The change from brand-name to ...... for early-stage breast cancer.
@ast
The change from brand-name to ...... for early-stage breast cancer.
@en
The change from brand-name to ...... for early-stage breast cancer.
@nl
prefLabel
The change from brand-name to ...... for early-stage breast cancer.
@ast
The change from brand-name to ...... for early-stage breast cancer.
@en
The change from brand-name to ...... for early-stage breast cancer.
@nl
P2093
P2860
P356
P1476
The change from brand-name to ...... for early-stage breast cancer.
@en
P2093
Alfred I Neugut
Jason D Wright
Jennifer Tsui
Sherry Glied
P2860
P356
10.1093/JNCI/DJU319
P407
P577
2014-10-27T00:00:00Z